Siren Biotechnology

Executive Summary

Siren Biotechnology is a clinical-stage biotech pioneering a universal AAV immuno-gene therapy platform for solid tumors, with lead candidate SRN-101 targeting recurrent high-grade glioma. The company combines adeno-associated virus (AAV) gene delivery with cytokine immunotherapy to stimulate a potent anti-tumor immune response. Founded in 2018 and based in San Diego, Siren has received FDA Fast Track Designation for SRN-101, underscoring the unmet need and potential for this therapy. The platform is designed to be 'universal'—enabling rapid adaptation to different tumor types by swapping cytokine payloads, potentially broadening its applicability beyond brain cancers. Siren is currently conducting Phase 1 clinical trials evaluating safety and preliminary efficacy in patients with recurrent high-grade glioma. Early data, if positive, could position the company for a pivotal trial and attract strategic partnerships. The company’s novel approach addresses key limitations of conventional immunotherapies, including poor tumor penetration and immunosuppressive microenvironments. With a strong preclinical foundation and regulatory support, Siren Biotechnology represents a promising investment opportunity in the gene therapy and immuno-oncology space.

Upcoming Catalysts (preview)

• Q1 2027Phase 1 interim data readout for SRN-101 in recurrent high-grade glioma65% success
• Q3 2026Initiation of Phase 2 expansion cohort or next trial70% success
• TBDPotential partnership or licensing deal for platform technology50% success